Quantitative methylation profiling of renal tumors and the discovery of a new generation of molecular markers

Future Oncology

Volumn 1, Issue 2, 2005, Pages 197-200

  Jerónimo, Carmen ^a,b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

epigenetics; gene methylation; molecular detection; renal cancer

Indexed keywords

RASSF1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADENOCARCINOMA; ARTICLE; DNA METHYLATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MUTATION; PAPILLARY CARCINOMA; PATHOLOGY; PROMOTER REGION;

ADENOCARCINOMA, CLEAR CELL; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; KIDNEY NEOPLASMS; MUTATION; PROMOTER REGIONS (GENETICS); TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 33646439763     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.1517/14796694.1.2.197     Document Type: Article

References (16)

1. Gonzalgo ML, Yegnasubramanian S, Yan G et al.: Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis. Clin. Cancer Res. 10 (21), 7276-7283 (2004)
2. Sidransky D: Emerging molecular markers of cancer. Nature Rev. Cancer 2, 210-219 (2002)
3. Herman JG and Baylin SB, Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349, 2042-2054 (2003)
4. Esteller M, Corn PG, Baylin SB et al.: A gene hypermethylation profile of human cancer. Cancer Res. 61, 3225-3229 (2001)
5. Herman JG, Graff J R, Myöhnen S et al.: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 93, 9821-9826 (1996)
6. Morris MR, Hesson LB, Wagner KJ et al.: Multigene methylation analysis of Wilms tumor and adult renal cell carcinoma. Oncogene 22, 6794-801 (2003)
7. Battagli C, Uzzo RG, Dulaimi E et al.: Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res. 63, 8695-8699 (2003)
8. Hoque MO, Begum S, Topaloglu O et al.: Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res. 64, 5511-5517 (2004)
9. Cairns P: Detection of promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Ann. NY Acad. Sci. 1022, 40-43 (2004)
10. Jerónimo C, Usadel H, Henrique R et al.: Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 60, 1131-1135 (2002)
11. Chan MW, Khan LW, Tang NLS et al.: Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin. Cancer Res. 8, 464-470 (2002)
12. Eads CA, Lord RV, Wickramasinghe K et al.: Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 61, 3410-3418 (2001)
13. Jerónimo C, Usadel H, Henrique R et al.: Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organconfined prostate adenocarcinoma. J. Natl Cancer Inst. 93, 1747-1752 (2001)
14. Jerónimo C, Henrique R, Hoque MO et al.: Quantitative RAR2 hypermethylation: a promising prostate cancer marker. Clin. Cancer Res. 10, 4010-4014 (2004)
15. Lafata JE, Simpkins J, Lamerato L et al.: The economic impact of false-positive cancer screens. Cancer Epidemiol. Biomarkers Prev. 13, 2126-2132 (2004)
16. World Health Organization classification of tumors. Pathology and genetics of tumors of the urinary system and male genital organs. Eble JN, Sauter G, Epstein JI (Eds.), IARC Press, Lyon, France (2004)